Prodia Subsidiary IPO: Half of Fresh Funds to Repay Debt
Jakarta, CNBC Indonesia - PT Prodia Diagnostic Line Tbk (PRDL) is preparing to list on the Indonesia Stock Exchange (BEI) by offering up to 522.9 million shares, equivalent to 30% of its post-IPO capital. The company is targeting proceeds of up to Rp62.75 billion from the corporate action.
Despite carrying a growth narrative in the medical devices sector, PRDL’s preliminary prospectus reveals several points that investors should scrutinise before hunting for the issuer’s initial shares.
The first note is the use of IPO funds, which is more oriented towards improving the balance sheet rather than aggressive expansion. Of the total funds raised, approximately Rp35.67 billion will be used to repay principal loans to PT Bank Central Asia Tbk (BCA) and PT Bank Pan Indonesia Tbk (Panin Bank). This means more than half of the IPO proceeds could potentially be used for debt repayment, rather than for building new factories, significantly increasing production capacity, or conducting large-scale market expansion.
Furthermore, the growth prospects offered by the company are highly dependent on government health spending. In the prospectus, the main risk faced by the company is explicitly stated as dependence on government spending in the health sector. PRDL’s growth narrative relies heavily on increases in the health budget, the Free Health Check-up programme, and government procurement of medical devices. Consequently, if there is budget efficiency or a change in national health policy priorities, the company’s growth potential could be affected.
From a financial performance perspective, the company’s profit recovery is not yet fully convincing. Based on financial reports, PRDL’s net profit reached approximately Rp35.8 billion in 2023, then dropped sharply to Rp10 billion in 2024 before recovering to around Rp17 billion in 2025.
Nevertheless, PRDL still holds several attractions. The company operates in the health diagnostics industry, which has long-term growth prospects in line with increasing demand for healthcare services in Indonesia. As of the end of 2025, the company had served more than 7,600 customers comprising hospitals, clinical laboratories, and community health centres across various regions of Indonesia. Additionally, the company’s financial reports received an unmodified opinion from an independent auditor and are supported by the presence of an international strategic partner through a 10% stake held by Diasys Diagnostic Systems GmbH.